For further information:
Richard Michaelson
Phone US:  (732) 649-9961
e-mail:  LifeSciencesResearch@LSRinc.net

May 4, 2005

LSR ANNOUNCES FIRST QUARTER RESULTS

East Millstone, New Jersey, May 4, 2005 – Life Sciences Research, Inc. (OTCBB: LSRI) announced today that revenues for the quarter ended March 31, 2005 were $43.3 million, operating income was $5.2 million, or 12.0% of revenues, and net income was $2.5 million.

Revenues for the quarter were 16.3% above the revenues for the same period in the prior year of $37.2 million. Excluding the effect of exchange rate movements, the increase was 13.6%.  The Company reported net income for the quarter ended March 31, 2005 of $2.5 million, compared with $1.4 million for the quarter ended March 31, 2004.   Net income per common share for the quarter ended March 31, 2005 was $0.20 compared with $0.12 in the quarter ended March 31, 2004. Net income per fully diluted share was $0.17 for the current quarter compared to $0.11 in the prior year.

The net income in the three months ended March 31, 2005 included Other Expenses of $0.7 million reflecting a non-cash foreign exchange remeasurement loss pertaining to the Convertible Capital Bonds. In the same period in the prior year, Other Income of $1.4 million comprised a non-cash foreign exchange remeasurement gain pertaining to the Convertible Capital Bonds.  Excluding these non cash items and related tax effect, net income for the current quarter was $3.0 million, or $0.21 per fully diluted share, compared to $0.4 million, or $0.04 per fully diluted share in the prior year and Earnings before Interest, Taxes, Depreciation and Amortization (“EBITDA”) was $7.5 million for the first quarter of 2005, or 17.4% of revenues, compared with $4.7 million, or 12.5% of revenues, for the same period in the prior year.

Net cash generated by operating activities totaled $0.6 million in the first quarter of 2005 ($1.5 million in first quarter 2004).  Net days sales outstanding at March 31, 2005 were 9 (14 at March 31, 2004 and 4 at December 31, 2004). Capital expenditure totaled $3.2 million in the first quarter of 2005, compared to $2.3 in the first quarter of 2004.  Cash on hand at March 31, 2005 was $29.9 million ($33.3 million at December 31, 2004). Long-term debt was $88.6 million at March 31, 2005 compared with $89.7 million at December 31, 2004, the reduction primarily due to exchange rate movements.

Net new business signings totaled $48.3 million for the first quarter of 2005.  Although this represented a decrease of 2% from the record first quarter orders in 2004, it was 11% up on the fourth quarter of last year and the Company’s second highest quarterly order level.  At March 31, 2005 backlog (booked on work) amounted to approximately $126 million, an increase of 13% above the level at March 31, 2004 (net of foreign currency effect).

Andrew Baker, LSR’s Chairman and CEO said, “The first quarter represented another record quarter for revenues and operating income, and continues the progress made by the Company during 2004.  Cash balances at the end of the quarter, although down on the traditionally high year-end balances, were $14.5 million up on a year ago.  Capital expenditure is also up slightly as we invest in new capital projects to strengthen our facilities and capabilities.”

Brian Cass, LSR’s President and Managing Director said, “In this quarter last year we saw very strong US orders whilst this year there has been a swing to Europe, which represented over half of our new business signings. Also our pharmaceutical chemistries reported strong order increases this quarter versus last year and accounted for some 30% of the total. These two things together emphasize both our geographic and service line diversity which adds strength to the business.  However, overall it is the consistently robust nature of business from the pharmaceutical sector which continues to drive the growth in our revenues and  this, together with our focus on operating efficiencies, has resulted in a year on year improvement in operating margins from 6% to 12% of revenues.  We have also started to invest in new capital projects to increase our capacity to serve this sector, particularly our specialist toxicology capabilities, and we look forward to this coming on stream at the end of the year.”

LSR will hold an investor conference call to discuss the quarter’s results on Thursday morning, May 5 2005 at 9:00 a.m. Eastern Time.  That call can be listened to by dialing (212) 547-0201; pass code 39138.  We suggest calling five minutes prior to the scheduled call.

Life Sciences Research, Inc. is a global contract research organization providing product development services to the pharmaceutical, agrochemical and biotechnology industries.  LSR brings leading technology and capability to support its clients in non-clinical safety testing of new compounds in early stage development and assessment.  The purpose of this work is to identify risks to humans, animals or the environment resulting from the use or manufacture of a wide range of chemicals which are essential components of LSR's clients' products.  The Company's services are designed to meet the regulatory requirements of governments around the world.  LSR operates research facilities in the United States (the Princeton Research Center, New Jersey) and the United Kingdom (Huntingdon and Eye, England).

This announcement contains statements that may be forward-looking as defined by the Private Securities Litigation Reform Act of 1995.  These statements are based largely on LSR’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond LSR’s control, as more fully described in the Company’s SEC filings, including its Form 10-K for the fiscal year ended December 31, 2004, as filed with the US Securities and Exchange Commission.

Life Sciences Research Inc.
Statement of Operations
Unaudited

 

Three months ended March 31

(Dollars in thousands, except per share data)

2005

 

2004

 

 

 

 

 

 

 

 

Net revenues

$43,294

 

$37,236

Cost of revenues

(31,082)

 

(29,435)

Gross profit

12,212

 

7,801

Selling, general and administrative expenses

(7,012)

 

(5,485)

Operating income

5,200

 

2,316

Interest income

23

 

14

Interest expense

(1,783)

 

(1,576)

Other (expense)/income

(732)

 

1,355

Income before income taxes

2,708

 

2,109

Income tax expense

(184)

 

(716)

Net income

$2,524

 

$1,393

 

 

 

 

 

 

 

 

Income per common share

 

 

 

- Basic

$0.20

 

$0.12

- Diluted

$0.17

 

$0.11

 

 

 

 

Weighted average common shares outstanding

 

 

 

- Basic     (000's)

12,454

 

12,040

- Diluted  (000's)

14,500

 

12,241

Life Sciences Research Inc.

Balance Sheet

(Dollars in thousands, except per share data)

March 31, 2005
Unaudited

 

December 31,2004
Audited

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$29,899

 

$33,341

Accounts receivable, net of allowance of $289 and $259 in 2005

and 2004, respectively

26,750

 

27,841

Unbilled receivables

10,727

 

11,516

Inventories

1,981

 

2,024

Prepaid expenses and other current assets

4,214

 

2,929

Total current assets

$73,571

 

$77,651

 

 

 

 

Property and equipment, net

109,278

 

109,999

Goodwill

885

 

901

Unamortized capital bonds issue costs

217

 

271

Deferred income taxes

10,932

 

11,253

Total assets

$194,883

 

$200,075

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)

 

 

 

Current liabilities:

 

 

 

Accounts payable

$13,052

 

$13,547

Accrued payroll and other benefits

4,251

 

4,024

Accrued expenses and other liabilities

18,141

 

19,987

Short-term debt

258

 

719

Fees invoiced in advance

33,208

 

37,574

Total current liabilities

$68,910

 

$75,851

 

 

 

 

Long-term debt

88,555

 

89,685

Pension liabilities

36,032

 

36,603

Total liabilities

$193,497

 

$202,139

Commitments and contingencies

 

 

 

Stockholders' equity/(deficit)

 

 

 

Preferred Stock, $0.01 par value. Authorized: 5,000,000

 

 

 

Issued and outstanding : None

-

 

-

Non-Voting Common Stock, $0.01 par value. Authorized: 5,000,000

 

 

 

Issued and outstanding: None

-

 

-

Voting Common Stock, $0.01 par value.  Authorized 50,000,000

 

 

 

Issued and outstanding at March 31, 2005:  12,488,639

 

 

 

(December 31, 2004: 12,441,281)

$125

 

$125

Paid in capital

75,744

 

75,671

Less: Promissory notes for the issuance of common stocks

(410)

 

(697)

Accumulated comprehensive loss

(34,158)

 

(34,724)

Accumulated deficit

(39,915)

 

(42,439)

Total stockholders' equity/(deficit)

1,386

 

$(2,064)

Total liabilities and stockholders' equity/(deficit)

$194,883

 

$200,075

Return to Top

Return to Press Release Menu

Return Home